IS2670B - Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun - Google Patents

Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun

Info

Publication number
IS2670B
IS2670B IS7296A IS7296A IS2670B IS 2670 B IS2670 B IS 2670B IS 7296 A IS7296 A IS 7296A IS 7296 A IS7296 A IS 7296A IS 2670 B IS2670 B IS 2670B
Authority
IS
Iceland
Prior art keywords
cop
vaccines
treatment
tyr
glu
Prior art date
Application number
IS7296A
Other languages
English (en)
Other versions
IS7296A (is
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IS7296A publication Critical patent/IS7296A/is
Publication of IS2670B publication Critical patent/IS2670B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IS7296A 2001-12-06 2004-06-03 Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun IS2670B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en) 2001-12-06 2002-12-05 Vaccine and method for treatment of motor neurone diseases

Publications (2)

Publication Number Publication Date
IS7296A IS7296A (is) 2004-06-03
IS2670B true IS2670B (is) 2010-09-15

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7296A IS2670B (is) 2001-12-06 2004-06-03 Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun

Country Status (24)

Country Link
US (1) US7351686B2 (is)
EP (1) EP1429800B1 (is)
JP (1) JP4542339B2 (is)
KR (1) KR20040081431A (is)
CN (2) CN1617736A (is)
AT (1) ATE422362T1 (is)
AU (1) AU2002353486B2 (is)
CA (1) CA2469092C (is)
CY (1) CY1109044T1 (is)
DE (1) DE60231131D1 (is)
DK (1) DK1429800T3 (is)
ES (1) ES2322566T3 (is)
HK (1) HK1067043A1 (is)
HU (1) HU228207B1 (is)
IL (1) IL160105A0 (is)
IS (1) IS2670B (is)
MX (1) MXPA04005537A (is)
NO (1) NO336231B1 (is)
NZ (1) NZ533356A (is)
PL (1) PL205469B1 (is)
PT (1) PT1429800E (is)
RU (1) RU2303996C2 (is)
SI (1) SI1429800T1 (is)
WO (1) WO2003047500A2 (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
EP1583506B1 (en) * 2003-01-07 2012-03-07 Yeda Research And Development Co., Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
JP5456235B2 (ja) 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
EP1701730B1 (en) 2003-12-09 2013-08-21 Yeda Research And Development Co., Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
NZ551236A (en) * 2004-05-07 2010-11-26 Peptimmune Inc Methods of treating disease with random copolymers
JP5241012B2 (ja) * 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
EP2195008A1 (en) 2007-09-24 2010-06-16 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
US9861686B2 (en) * 2011-12-05 2018-01-09 Ben-Gurion University Of The Negev Research & Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
JP6276252B2 (ja) * 2012-03-26 2018-02-07 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ． Ｌｔｄ アルツハイマー病の診断のための細胞マーカーおよびアルツハイマー病の進行の細胞マーカー
US20150238582A1 (en) 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
WO1999034827A1 (en) 1998-07-21 1999-07-15 Yeda Research And Development Co. Ltd. Activated t-cells and their uses
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (ja) 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド 細胞、神経系−特異的抗原およびそれらの用途
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
AU780188B2 (en) * 2000-01-20 2005-03-03 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
JP4328090B2 (ja) 2000-06-07 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経細胞の保護療法におけるコポリマー１、関連ペプチドおよびポリペプチドならびにそれらによって処理されたｔ細胞の使用
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
PT1429800E (pt) 2009-04-27
HK1067043A1 (en) 2005-04-01
NO20042833L (no) 2004-08-12
WO2003047500A3 (en) 2004-03-18
JP4542339B2 (ja) 2010-09-15
CY1109044T1 (el) 2014-07-02
RU2004120536A (ru) 2005-03-27
WO2003047500A2 (en) 2003-06-12
US7351686B2 (en) 2008-04-01
IS7296A (is) 2004-06-03
HUP0500039A2 (hu) 2005-03-29
ES2322566T3 (es) 2009-06-23
DK1429800T3 (da) 2009-04-27
HUP0500039A3 (en) 2010-01-28
NO336231B1 (no) 2015-06-22
CA2469092A1 (en) 2003-06-12
EP1429800A4 (en) 2006-03-22
JP2005515198A (ja) 2005-05-26
RU2303996C2 (ru) 2007-08-10
ATE422362T1 (de) 2009-02-15
SI1429800T1 (sl) 2009-08-31
AU2002353486B2 (en) 2009-01-15
EP1429800B1 (en) 2009-02-11
PL205469B1 (pl) 2010-04-30
AU2002353486A1 (en) 2003-06-17
DE60231131D1 (de) 2009-03-26
CA2469092C (en) 2013-02-19
US20050220802A1 (en) 2005-10-06
CN102151330A (zh) 2011-08-17
IL160105A0 (en) 2004-06-20
EP1429800A2 (en) 2004-06-23
CN1617736A (zh) 2005-05-18
NZ533356A (en) 2006-10-27
HU228207B1 (hu) 2013-01-28
MXPA04005537A (es) 2004-11-01
KR20040081431A (ko) 2004-09-21
CN102151330B (zh) 2017-04-12
PL370070A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
MXPA05002814A (es) Formulacion para agentes lipofilicos.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
DE60224508D1 (de) Wti-modifiziertes peptid
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
HK1068606A1 (en) Novel aminobenzoephenones
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP1958960A3 (en) A process for the preparation of a non-toxic anthrax vaccine
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
MXPA02010173A (es) Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
ATE515258T1 (de) Mukosales verabreichungssytem
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
WO2002098359A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
RU2350351C2 (ru) Композиции и лекарственные формы на основе гастрина, методы применения и получения
EP1422238A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU4300700A (en) Inactivated cytokines for immunisation
RU2001124669A (ru) Способ профилактики паратифа телят